TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33677049

Group type: EXPERIMENTAL
Intervention: Whole-lung low-dose radiation therapy (LDRT) 1 Gy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham irradiation (sham-RT)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Whole-lung low-dose radiation therapy (LDRT)
Number of subjects: 22
Study: 32067817

Group type: EXPERIMENTAL
Intervention: EV71 vaccine from Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) for the first dose and Sinovac vaccine for the second dose (Group D)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Single vaccine from one manufacturer (two groups)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Mixed schedules using vaccines from two manufacturers (two groups)
Number of subjects: 300
Study: 32783199

Group type: EXPERIMENTAL
Intervention: Depressed participants
Number of subjects: 986

Group type: EXPERIMENTAL
Intervention: Anxious participants
Number of subjects: 986
Study: 35271378

Group type: EXPERIMENTAL
Intervention: Telehealth backgrounds (six different virtual backgrounds)
Number of subjects: 0
Study: 36333741

Group type: EXPERIMENTAL
Intervention: Flexible charrière‐4 feeding tube inserted using Magill forceps (group 1)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Semi‐rigid catheter (group 2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 31
Study: 32976633

Group type: EXPERIMENTAL
Intervention: Permanent supportive housing (PSH)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 423
Study: 35446282

Group type: EXPERIMENTAL
Intervention: Complex Training (CPX)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Compound Training (CPD)
Number of subjects: 10
Study: 36045387

Group type: EXPERIMENTAL
Intervention: internet-based Unified Protocol (iUP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: enhanced waiting list control (eWLC)
Number of subjects: 120
Study: 32334292

Group type: EXPERIMENTAL
Intervention: USG FICB (fascia iliaca compartment block)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Sham FICB (control group)
Number of subjects: 182
Study: 36184755

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 0
Study: 33693461

Group type: EXPERIMENTAL
Intervention: HADM (Human Acellular Dermal Matrix)
Number of subjects: 68

Group type: COMPARATOR
Intervention: BADM (Bovine Acellular Dermal Matrix)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HADM
Number of subjects: 68

Group type: COMPARATOR
Intervention: BADM
Number of subjects: 68
Study: 32268344

Group type: EXPERIMENTAL
Intervention: 150 mg of levodopa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg of haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35288419

Group type: EXPERIMENTAL
Intervention: Valganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated and uninfected)
Number of subjects: 0
Study: 34187530

Group type: EXPERIMENTAL
Intervention: LPV (Vt = 6 ml/kg of ideal body weight, respiratory rate initially set at 16 breaths/min, PEEP at 5 cmH2O, recruitment manoeuvre applied)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (Vt = 10 ml/kg of ideal body weight, respiratory rate initially set at 6–8 breaths/min, no PEEP, no recruitment manoeuvre)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LPV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 32838798

Group type: EXPERIMENTAL
Intervention: 3D printing technology with 3D chest CT reconstruction (Group A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Chest CT scans with image enhancement for 3D reconstruction (Group B)
Number of subjects: 89
Study: 33487255

Group type: EXPERIMENTAL
Intervention: DHA supplementation (650 mg DHA, 3 times/week, post-HD session)
Number of subjects: 52
Study: 32507538

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D3) 4,000 IU or 7,000 IU daily for 6 and 12 weeks
Number of subjects: 44
Study: 34397393

Group type: EXPERIMENTAL
Intervention: Internet-based warfarin management
Number of subjects: 721

Group type: COMPARATOR
Intervention: Conventional warfarin management
Number of subjects: 721
Study: 32012841

Group type: EXPERIMENTAL
Intervention: Water-based exercise program (60 min sessions, 3 times per week for 17 weeks)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Normal weight at the start of pregnancy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Overweight/obesity
Number of subjects: 129
Study: 36120775

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 33650977

Group type: EXPERIMENTAL
Intervention: Heali mobile app and educational materials
Number of subjects: 58

Group type: COMPARATOR
Intervention: Educational materials
Number of subjects: 58
Study: 35710572

Group type: EXPERIMENTAL
Intervention: Heterologous boost COVID‐19 vaccine regimens (intervention groups 1–4)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Homologous boost regimen (control arm)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 600
Study: 32721007

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE) alone
Number of subjects: 27347

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Number of subjects: 27347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27347
Study: 35489363

Group type: EXPERIMENTAL
Intervention: Lenvatinib (oral 20 mg per day) plus Pembrolizumab (intravenous 200 mg every 21 days)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: Sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off)
Number of subjects: 1069
Study: 33477172

Group type: EXPERIMENTAL
Intervention: General practitioners' estimation of prevalence of non-dialysis chronic kidney disease
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Use of urine dipstick test for proteinuria diagnosis
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Use of albumin/creatinine-ratio for proteinuria diagnosis
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Adjustment of high blood pressure and diabetes mellitus
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Competence in treating non-dialysis chronic kidney disease
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: Impact of working experience on tool selection
Number of subjects: 1130
Study: 33142973

Group type: COMPARATOR
Intervention: Traditional training (TT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback manikins (FT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mobile phone applications (AP)
Number of subjects: 0
Study: 36084276

Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Total body irradiation plus cyclophosphamide (TBI-Cy)
Number of subjects: 550
Study: 33942376

Group type: EXPERIMENTAL
Intervention: Inosine (active treatment)
Number of subjects: 297
Study: 33581174

Group type: EXPERIMENTAL
Intervention: 80 mg MET409
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 50 mg MET409
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32483272

Group type: EXPERIMENTAL
Intervention: TET1 expression
Number of subjects: 0
Study: 35799554

Group type: EXPERIMENTAL
Intervention: VivaSight double-lumen tube (VDLT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional double-lumen tube (cDLT)
Number of subjects: 100
Study: 34648598

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory diet (1100 kcal/day, five days/week)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet (usual Swedish intake)
Number of subjects: 50
Study: 32648183

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic resection for rectal cancer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Robotic technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 35911222

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 83
Study: 32389808

Group type: EXPERIMENTAL
Intervention: LIPP (lifestyle intervention program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 0
Study: 33893936

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 101

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Baseline levels of CD36+/CD61+/AV+ MPs
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ROC-curve model for CD36+/CD61+/AV+ MPs
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: TEG examination
Number of subjects: 101
Study: 32633541

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: All antipsychotics combined
Number of subjects: 119
Study: 32873681

Group type: EXPERIMENTAL
Intervention: (extended) pleurectomy decortication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 35932912

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study: 32636444

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 100
Study: 35243909

Group type: EXPERIMENTAL
Intervention: Class-based face-to-face body awareness lessons
Number of subjects: 20

Group type: COMPARATOR
Intervention: Home-based individually performed body awareness lessons
Number of subjects: 20
Study: 32634565

Group type: EXPERIMENTAL
Intervention: Intra-operative optical coherence tomography (OCT) control in addition to standard angiogram
Number of subjects: 166

Group type: COMPARATOR
Intervention: Standard angiogram alone
Number of subjects: 166
Study: 35557513

Group type: EXPERIMENTAL
Intervention: Intensive treatment group (CDDP 20 pills three times per day)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard treatment group (10 pills CDDP and 10 pills placebo three times per day)
Number of subjects: 250
Study: 33385279

Group type: EXPERIMENTAL
Intervention: TransPrEP intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 89
Study: 33621406

Group type: COMPARATOR
Intervention: LPR patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Patients with OSAS, LPR, and GERD
Number of subjects: 89
Study: 35426736

Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA) on active points
Number of subjects: 133

Group type: COMPARATOR
Intervention: Sham Auricular Acupressure (SAA)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Auricular Acupressure (AA)
Number of subjects: 133
Study: 33059380

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia with 0.5% tetracaine-HCl ophthalmic solution applied three times at 30-second intervals after wound closure
Number of subjects: 50

Group type: COMPARATOR
Intervention: No topical anaesthesia (control group)
Number of subjects: 50
Study: 35144570

Group type: EXPERIMENTAL
Intervention: Inquiry‐Based Stress Reduction counseling session (2 hours weekly for 6 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study: 33244872

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alpha1‐PI[h] therapy (90 or 180 mg/kg weekly for 13 or 26 weeks)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) alpha1‐PI[h] therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 35093007

Group type: EXPERIMENTAL
Intervention: HIV-1 DNA < 3 log10 copies/million PBMC
Number of subjects: 1013
Study: 32139400

Group type: EXPERIMENTAL
Intervention: Minor Ailment Service (MAS)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 894
Study: 35344808

Group type: EXPERIMENTAL
Intervention: 2-Hz low-frequency stimulation of the fornicodorsocommissural tract
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5-Hz low-frequency stimulation of the fornicodorsocommissural tract
Number of subjects: 5

Group type: COMPARATOR
Intervention: Low-frequency stimulation (2Hz or 5Hz)
Number of subjects: 5
Study: 32375763

Group type: EXPERIMENTAL
Intervention: Mobile application after rehabilitation
Number of subjects: 740

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 740
Study: 36326771

Group type: EXPERIMENTAL
Intervention: Femoral periarterial block (FAB)
Number of subjects: 42
Study: 33481300

Group type: EXPERIMENTAL
Intervention: Supervised 12-week programme of aerobic and muscle strengthening exercise with Smartband
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standardized advice about physical activity
Number of subjects: 100
Study: 35841457

Group type: EXPERIMENTAL
Intervention: Mongersen (oral antisense oligonucleotide targeting Smad7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mongersen
Number of subjects: 0
Study: 32698812

Group type: EXPERIMENTAL
Intervention: Audit and Feedback (A&F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Audit and Feedback plus External Facilitation (A&F + EF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35077474

Group type: EXPERIMENTAL
Intervention: rasagiline (1 mg/day)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: rasagiline (0.5 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2
Study: 33757474

Group type: EXPERIMENTAL
Intervention: High dose cranberry proanthocyanidin extract (2 × 18.5 mg daily, n = 72)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Low dose cranberry proanthocyanidin extract (2 × 1 mg daily, n = 73)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: High dose cranberry proanthocyanidin extract
Number of subjects: 145
Study: 32833477

Group type: EXPERIMENTAL
Intervention: Mindfulness based cognitive therapy ‐ perinatal depression (MBCT‐PD)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 74
Study: 35300902

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided femoral nerve block (UGFN)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no UGFN)
Number of subjects: 48
Study: 34405737

Group type: EXPERIMENTAL
Intervention: Oficina da Lembrança (OL) program for 12 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 64
Study: 32461297

Group type: EXPERIMENTAL
Intervention: Adalimumab interval lengthening (every 3 weeks, then every 4 weeks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Adalimumab EOW (every other week)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Adalimumab interval lengthening
Number of subjects: 174
Study: 36319057

Group type: EXPERIMENTAL
Intervention: Methenamine hippurate 1 g, two times per day for 6 months
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo tablets, two times per day for 6 months
Number of subjects: 400
Study: 33109586

Group type: EXPERIMENTAL
Intervention: α-type-1 DC vaccine
Number of subjects: 16
Study: 36108648

Group type: EXPERIMENTAL
Intervention: Systematic search for pulmonary embolism (PE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 35130832

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 480

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study: 32245508

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) for 4 weeks in the START block, followed by a switch to active drug for the placebo group.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) in the STOP block.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in the START block (initially), switched to HCQ after 4 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in the STOP block.
Number of subjects: 0
Study: 34521506

Group type: EXPERIMENTAL
Intervention: Custom zirconia abutment with a bonded titanium insert
Number of subjects: 80

Group type: COMPARATOR
Intervention: Custom titanium abutment
Number of subjects: 80
Study: 34845077

Group type: EXPERIMENTAL
Intervention: Hyfosy with additional tubal flushing with oil soluble contrast medium (OSCM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hyfosy without additional flushing
Number of subjects: 12
Study: 37246674

Group type: EXPERIMENTAL
Intervention: Same Arm Movement Therapy for 8 weeks (45 min supervised sessions 3 times a week and structured independent sessions twice a week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Constraint Induced Movement Therapy for 8 weeks (2 hours per day, 5 days a week, with restriction of the non-affected extremity for 10 hours a day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 22
Study: 32532583

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine triphosphate (ATP) infusion at 210 μg/kg/min (IVATP210)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine triphosphate (ATP) infusion at 150 μg/kg/min (IVATP150)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Intracoronary administration of nicorandil 2 mg (ICNIC2mg)
Number of subjects: 208
Study: 32304185

Group type: EXPERIMENTAL
Intervention: Occlusal appliance (OA)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Relaxation therapy (RT) and information only (Co)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Supplementary treatment (ST)
Number of subjects: 167
Study: 36424550

Group type: EXPERIMENTAL
Intervention: Intervention (daily automated flags in CHORUS™)
Number of subjects: 15875

Group type: COMPARATOR
Intervention: Control (existing retention efforts)
Number of subjects: 15875
Study: 32844453

Group type: EXPERIMENTAL
Intervention: Letermovir prophylaxis
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 100
Study: 32660748

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Atezolizumab vs Chemotherapy
Number of subjects: 1262
Study: 36031632

Group type: EXPERIMENTAL
Intervention: Insight impairment (measured by PANSS Item G12)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Insight impairment (PANSS Item G12 rating ≥ 5)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Insight impairment (PANSS Item G12 rating < 5)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: SF-12 Mental Component Summary (MCS) scores
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Insight impairment
Number of subjects: 1431
Study: 34995275

Group type: EXPERIMENTAL
Intervention: Oseltamivir phosphate 75mg BID for a maximum of five days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 33513242

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (Nabs) measured using a lentiviral vector‐based SARS‐CoV‐2 neutralization assay
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (Nabs) in patients with diabetes
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nab response across glucose levels
Number of subjects: 150
Study: 32838803

Group type: EXPERIMENTAL
Intervention: MCH handbook distribution and supplementary interventions including training for healthcare providers and community mobilisation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional use of two stand-alone HBRs (Control).
Number of subjects: 0
Study: 35334535

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical technique (MIS) - percutaneous chevron osteotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Open chevron osteotomy (OC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (MIS and OC)
Number of subjects: 50
Study: 33440343

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mental Fatigue (MF)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: SR and MF combined
Number of subjects: 19
Study: 36028158

Group type: EXPERIMENTAL
Intervention: Alto Stent Graft System
Number of subjects: 75
Study: 33950945

Group type: EXPERIMENTAL
Intervention: Acupuncture (true acupuncture using a uniquely designed press tack needle)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo acupuncture (placebo treatment using a similarly designed press tack needle without the needle element)
Number of subjects: 72
Study: 35305222

Group type: EXPERIMENTAL
Intervention: CBT4CBT‐Spanish (culturally adapted Spanish‐language version of web‐based cognitive behavioral therapy)
Number of subjects: 89
Study: 33191252

Group type: EXPERIMENTAL
Intervention: Time-lapse imaging system (TLS)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Conventional incubator
Number of subjects: 730
Study: 34489516

Group type: EXPERIMENTAL
Intervention: Nurse-led, telephone-based follow-up including medical titration
Number of subjects: 962

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 962
Study: 33236646

Group type: EXPERIMENTAL
Intervention: SIC + Octagam (30 g/day for 5 days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: SIC only (control group)
Number of subjects: 93
Study: 36282451

Group type: EXPERIMENTAL
Intervention: Empowerment Program (EP), held for 5 weeks, one session of 20 to 30 min each week
Number of subjects: 70
Study: 34062148

Group type: EXPERIMENTAL
Intervention: Informal integration
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Shared clinicians
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Care coordinators
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Shared quality/safety activities
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Formal integration
Number of subjects: 500

Group type: COMPARATOR
Intervention: For-profit SNFs
Number of subjects: 500

Group type: COMPARATOR
Intervention: Metropolitan areas
Number of subjects: 500

Group type: COMPARATOR
Intervention: Midwest SNFs
Number of subjects: 500
Study: 35143095

Group type: EXPERIMENTAL
Intervention: Thrombectomy alone
Number of subjects: 649

Group type: COMPARATOR
Intervention: Combination therapy (thrombectomy preceded by intravenous alteplase)
Number of subjects: 649